Washington, D.C.- Congresswoman Diana Harshbarger released the following statement following news from the Internal Revenue Service (IRS) on extending the tax filing deadline to May 17, 2021.
Rep. Diana Harshbarger has introduced her first bill, legislation that she says could lead to lower prescription drug costs. To read the article, visit here.
Rep. Diana Harshbarger voted against two Democratic efforts to expand background check requirements for firearms sales. Click here to read the full article.
Washington, D.C.- Congresswoman Diana Harshbarger released the following statement on introducing the PBM Accountability Study Act of 2021. The bill calls for a study into ways to increase transparency of pharmacy benefit managers (PBMs), which are the middlemen who negotiate payments between health insurers, pharmacies, and drug companies.
Washington, D.C.- Congresswoman Diana Harshbarger released the following statement after her votes against Democrat-led bills that infringe upon law-abiding citizens’ Second Amendment Rights: H.R. 8, the Background Checks Act, and H.R. 1446, the Enhanced Background Checks Act of 2021.
Washington, D.C.- Congresswoman Diana Harshbarger released the following statement outlining her opposition to the Democrats’ partisan $1.9 trillion stimulus bill.
WASHINGTON (WJHL) — Neopharma’s pharmaceutical manufacturing facility in Bristol will keep its critical infrastructure designation even after the COVID-19 pandemic is over.
Kingsport, TN- Congresswoman Diana Harshbarger released the following statement regarding the critical infrastructure designation for the Neopharma pharmaceutical manufacturing facility located in Bristol, TN. The plant is the only domestic turn-key facility to allow for the full production of penicillin.
U.S. Capitol Building
Washington, D.C.- Congresswoman Diana Harshbarger released the following statement today regarding the partisan budget reconciliation proposal by President Biden and Congressional Democrats.